Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA, Pötschger U, Moreno L, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, Elliot M, Wieczorek A, Laureys G, Kogner P, Malis J, Ruud E, Beck-Popovic M, Schleiermacher G, Valteau-Couanet D, Ladenstein R. Morgenstern DA, et al. Pediatr Blood Cancer. 2018 Nov;65(11):e27363. doi: 10.1002/pbc.27363. Epub 2018 Jul 17. Pediatr Blood Cancer. 2018. PMID: 30015396
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, Ribeiro A, Mosseri V, Rubie H, Munzer C, Thomas C, Valteau-Couanet D, Auvrignon A, Plantaz D, Delattre O, Couturier J; Société Française des Cancers de l'Enfant (SFCE). Schleiermacher G, et al. Br J Cancer. 2007 Jul 16;97(2):238-46. doi: 10.1038/sj.bjc.6603820. Epub 2007 Jun 19. Br J Cancer. 2007. PMID: 17579628 Free PMC article.
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Janoueix-Lerosey I, et al. Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398. Nature. 2008. PMID: 18923523
Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Janoueix-Lerosey I, et al. J Clin Oncol. 2009 Mar 1;27(7):1026-33. doi: 10.1200/JCO.2008.16.0630. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171713
Opsoclonus-myoclonus in children associated or not with neuroblastoma.
Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, Sarnacki S, Martelli H, Desguerre I, Tardieu M. Krug P, et al. Eur J Paediatr Neurol. 2010 Sep;14(5):400-9. doi: 10.1016/j.ejpn.2009.12.005. Epub 2010 Jan 27. Eur J Paediatr Neurol. 2010. PMID: 20110181
Medulloblastoma in young children.
Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre ML, Grill J. Rutkowski S, et al. Pediatr Blood Cancer. 2010 Apr;54(4):635-7. doi: 10.1002/pbc.22372. Pediatr Blood Cancer. 2010. PMID: 20146217 Review.
Accumulation of segmental alterations determines progression in neuroblastoma.
Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O. Schleiermacher G, et al. J Clin Oncol. 2010 Jul 1;28(19):3122-30. doi: 10.1200/JCO.2009.26.7955. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516441
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, Pötschger U, Pearson A. Ladenstein R, et al. J Clin Oncol. 2010 Jul 20;28(21):3516-24. doi: 10.1200/JCO.2009.27.3524. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567002 Clinical Trial.
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J. Rubie H, et al. J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20. J Clin Oncol. 2011. PMID: 21172879 Clinical Trial.
A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age.
Monnereau-Laborde S, Munzer C, Valteau-Couanet D, Ansoborlo S, Coze C, Chastagner P, Rubie H, Demeocq F, Stephan JL, Hartmann O, Perel Y. Monnereau-Laborde S, et al. Pediatr Blood Cancer. 2011 Dec 1;57(6):965-71. doi: 10.1002/pbc.23232. Epub 2011 Jul 8. Pediatr Blood Cancer. 2011. PMID: 21744481 Clinical Trial.
216 results